Our vision is to be a leader in cancer immunotherapy improving patient treatment through novel monoclonal antibodies, inducing programmed cell death in cancer cells. Cancer treatment has generally been based on treatment with drugs and modalities that are cytotoxic to both cancer and healthy cells. Advances in immunotherapy open new possibilities for selective targeting of cancer cells. Caedo Oncology develops new strategies for monoclonal antibody-based therapy centered around activation of distinctive pathways for cell death in cancer cells. The company was established in November 2020 based on research performed at Oslo University Hospital.